PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure

Mo, Lingxuan; Song, Jae Geun; Lee, Hankyu; Zhao, Mingguo; Kim, Hyeon Young; Lee, Yoon Ji; Ko, Hyuk Wan; Han, Hyo Kyung

doi:10.1016/j.nano.2017.12.003

Cited by 62 publications

(29 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enzymes are proteins with extreme biorecognition ability and catalytic function in chemical reactions. They can be used as diagnostic markers for pathologies or target-therapeutics, since some diseases present differences in their expression compared to healthy tissues ( 123 , 124 ). The over expression of proteases and phospholipases in tumor tissue, when compared to the normal tissue, has been explored to develop enzyme-triggered liposomes ( 125 , 126 ).…”

Section: Triggered Drug Release By Endogenous Stimulimentioning

confidence: 99%

“…The oxygen partial pressure on some tumor tissues can be as low as 5–10 mm Hg, compared to the healthy tissue where it is near 30–50 mm Hg ( 132 , 133 ). Due to this significant difference in the amount of oxygen, hypoxia is a promising target for cancer therapy ( 124 ). It is reported that the pathological phenomenon of hypoxia causes an increase in reductive stress, resulting in overexpression of nitroreductase, azoreductase, and quinone reductase ( 134 ).That in mind, pro-drugs that are activated to form the cytotoxic agent in hypoxia regions were designed ( 132 ), as well as hypoxia-triggered drug delivery systems to release drugs to hypoxic sites ( 133 ).…”

Section: Triggered Drug Release By Endogenous Stimulimentioning

confidence: 99%

See 1 more Smart Citation

Triggered Drug Release From Liposomes: Exploiting the Outer and Inner Tumor Environment

et al. 2021

View full text Add to dashboard Cite

Since more than 40 years liposomes have being extensively studied for their potential as carriers of anticancer drugs. The basic principle behind their use for cancer treatment consists on the idea that they can take advantage of the leaky vasculature and poor lymphatic drainage present at the tumor tissue, passively accumulating in this region. Aiming to further improve their efficacy, different strategies have been employed such as PEGlation, which enables longer circulation times, or the attachment of ligands to liposomal surface for active targeting of cancer cells. A great challenge for drug delivery to cancer treatment now, is the possibility to trigger release from nanosystems at the tumor site, providing efficacious levels of drug in the tumor. Different strategies have been proposed to exploit the outer and inner tumor environment for triggering drug release from liposomes and are the focus of this review.

show abstract

Section: Triggered Drug Release By Endogenous Stimulimentioning

confidence: 99%

Section: Triggered Drug Release By Endogenous Stimulimentioning

confidence: 99%

Triggered Drug Release From Liposomes: Exploiting the Outer and Inner Tumor Environment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This slow-release profile suggests that most of the SFN remained associated with the LNCs, which may be beneficial, as it would allow sufficient time for cells to capture the loaded LNCs. High encapsulation efficiency and slow drug release have also been reported for liposomal formulations of SFN (Liu et al., 2015 ; Mo et al., 2018 ).…”

Section: Discussionmentioning

confidence: 93%

“…Nanoformulations of SFN are of potential interest, as they combine the intrinsic toxicity of the drug with a nanodelivery approach. Many studies have assessed the use of SFN encapsulated or entrapped in various nanocarriers, including polymeric carriers (Zhang et al., 2013 ; Craparo et al., 2014 ; Gao et al., 2015 ; Li et al., 2015 ; Liu et al., 2015 , 2016 ; Lin et al., 2016 ; Yang et al., 2016 ), lipid-based carriers (Zhang et al., 2014 ; Bondì et al., 2015 ; Grillone et al., 2015 ; Liu et al., 2015 ; Xiao et al., 2016 ; Yang et al., 2016 ; Mo et al., 2018 ; Benizri et al., 2018 ), and polymer-lipid hybrid nanoparticles (Zhang et al., 2016 , 2017 ). These nanocarriers have given promising results in the liver and gastric cancer models.…”

Section: Discussionmentioning

confidence: 99%

Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma

et al. 2018

View full text Add to dashboard Cite

Anticancer agents that target both tumor cells and angiogenesis are of potential interest for glioblastoma (GB) therapy. One such agent is sorafenib (SFN), a tyrosine kinase inhibitor. However, poor aqueous solubility and undesirable side effects limit its clinical application, including local treatment. We encapsulated SFN in lipid nanocapsules (LNCs) to overcome these drawbacks. LNCs are nanocarriers formulated according to a solvent-free process, using only components that have received regulatory approval. SFN-LNCs had a diameter of 54 ± 1 nm, high encapsulation efficiency (>90%), and a drug payload of 2.11 ± 0.03 mg/g of LNC dispersion. They inhibited in vitro angiogenesis and decreased human U87MG GB cell viability similarly to free SFN. In vivo studies showed that the intratumoral administration of SFN-LNCs or free SFN in nude mice bearing an orthotopic U87MG human GB xenograft decreased the proportion of proliferating cells in the tumor relative to control groups. SFN-LNCs were more effective than free SFN for inducing early tumor vascular normalization, characterized by increases in tumor blood flow and decreases in tumor vessel area. These results highlight the potential of LNCs as delivery systems for SFN. The vascular normalization induced by SFN-LNCs could be used to improve the efficacy of chemotherapy or radiotherapy for treating GB.

show abstract

“…In previous reports, LNP was modified with HA by electrostatic interaction between cationic LNP and anionic HA molecules 21,37,38 . Data on the characterization of these carriers are shown in Table 1.…”

Section: Optimization Of Hal-modified Lnps With Cd44-positive Mpm Cellsmentioning

confidence: 99%

Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid–Lipid Conjugate

Sakurai

Kato

Hida

et al. 2019

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure

Cited by 62 publications

References 39 publications

Triggered Drug Release From Liposomes: Exploiting the Outer and Inner Tumor Environment

Triggered Drug Release From Liposomes: Exploiting the Outer and Inner Tumor Environment

Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma

Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid–Lipid Conjugate

Contact Info

Product

Resources

About